$IRWD Cashflow Statement | Understand Stock

$IRWD

$3.51 +$0.01 (0.29%) Close

$IRWD Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net income
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
Loss on disposal of property and equipment
Share-based compensation expense
Change in fair value of note hedge warrants
Change in fair value of convertible note hedges
Deferred income taxes (including benefit from valuation allowance release)
Acquired in-process research and development
Non-cash interest expense
Non-cash lease expense
Deferred income taxes
Changes in assets and liabilities:
Accounts receivable, net
Prepaid expenses and other current assets
Operating lease right-of-use assets
Other assets
Accounts payable and accrued expenses
Accrued research and development costs
Operating lease liabilities
Other liabilities
Net cash provided by (used in) continuing operating activities

Net cash provided by operating activities
Cash flows from investing activities:
Purchases of property and equipment
Net cash (used in) continuing investing activities
Acquisition of VectivBio Holding AG, net of cash acquired
Net cash used in investing activities

Cash flows from financing activities:
Proceeds from exercise of stock options and employee stock purchase plan
Taxes paid related to net share settlement of share-based awards
Purchase of subsidiary shares from noncontrolling interests
Repayment of 2024 Convertible Notes
Repurchases of common stock
Proceeds from revolving credit facility
Costs associated with revolving credit facility
Repayments of revolving credit facility
Net cash provided by (used in) financing activities

Effect of exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Supplemental cash flow disclosure:
Cash paid for interest
Cash paid for income taxes
Stock repurchases payable in accrued expenses
Stock option exercise proceeds receivable in other current assets

Comments